{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:21:16Z","timestamp":1773418876566,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["R01CA235152"],"award-info":[{"award-number":["R01CA235152"]}]},{"DOI":"10.13039\/100018576","name":"Harrington Discovery Institute, University Hospitals","doi-asserted-by":"publisher","award":["Gund-Harrington Scholars Award"],"award-info":[{"award-number":["Gund-Harrington Scholars Award"]}],"id":[{"id":"10.13039\/100018576","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s11095-024-03679-1","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T18:01:43Z","timestamp":1709661703000},"page":"807-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intravitreal Delivery of PEGylated-ECO Plasmid DNA Nanoparticles for Gene Therapy of Stargardt Disease"],"prefix":"10.1007","volume":"41","author":[{"given":"Da","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lehrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-Rong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"3679_CR1","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/08164622.2021.1880863","volume":"104","author":"ML Hu","year":"2021","unstructured":"Hu ML, et al. Gene therapy for inherited retinal diseases: progress and possibilities. Clin Exp Optom. 2021;104:444\u201354.","journal-title":"Clin Exp Optom"},{"key":"3679_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.drudis.2019.01.019","volume":"24","author":"JJ Darrow","year":"2019","unstructured":"Darrow JJ. Luxturna: FDA documents reveal the value of a costly gene therapy. Drug Discovery Today. 2019;24:949\u201354.","journal-title":"Drug Discovery Today"},{"key":"3679_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ymthe.2020.11.029","volume":"29","author":"AM Maguire","year":"2021","unstructured":"Maguire AM, Bennett J, Aleman EM, Leroy BP, Aleman TS. Clinical perspective: treating RPE65-associated retinal dystrophy. Mol Ther. 2021;29:442\u201363.","journal-title":"Mol Ther"},{"key":"3679_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1211\/0022357011776603","volume":"53","author":"AJ Phillips","year":"2001","unstructured":"Phillips AJ. The challenge of gene therapy and DNA delivery. J Pharm Pharmacol. 2001;53:1169\u201374.","journal-title":"J Pharm Pharmacol"},{"key":"3679_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1442-9071.2011.02649.x","volume":"40","author":"PC Issa","year":"2012","unstructured":"Issa PC, MacLaren RE. Non-viral retinal gene therapy: a review. Clin Experiment Ophthalmol. 2012;40:39\u201347.","journal-title":"Clin Experiment Ophthalmol"},{"key":"3679_CR6","doi-asserted-by":"publisher","first-page":"7158","DOI":"10.1016\/j.biomaterials.2013.06.002","volume":"34","author":"A Koirala","year":"2013","unstructured":"Koirala A, Conley SM, Naash MI. A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium. Biomaterials. 2013;34:7158\u201367.","journal-title":"Biomaterials"},{"key":"3679_CR7","first-page":"456","volume":"10","author":"SM Conley","year":"2008","unstructured":"Conley SM, Cai X, Naash MI. Non-viral ocular gene therapy: assessment and future directions. Curr Opin Mol Ther. 2008;10:456.","journal-title":"Curr Opin Mol Ther"},{"key":"3679_CR8","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.addr.2006.07.023","volume":"58","author":"C Bloquel","year":"2006","unstructured":"Bloquel C, et al. Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliv Rev. 2006;58:1224\u201342.","journal-title":"Adv Drug Deliv Rev"},{"key":"3679_CR9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.drudis.2008.09.012","volume":"14","author":"R Naik","year":"2009","unstructured":"Naik R, Mukhopadhyay A, Ganguli M. Gene delivery to the retina: focus on non-viral approaches. Drug Discovery Today. 2009;14:306\u201315.","journal-title":"Drug Discovery Today"},{"key":"3679_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijpharm.2008.04.023","volume":"360","author":"A del Pozo-Rodriguez","year":"2008","unstructured":"del Pozo-Rodriguez A, Delgado D, Solinis M, Gascon A, Pedraz J. Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int J Pharm. 2008;360:177\u201383.","journal-title":"Int J Pharm"},{"key":"3679_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejpb.2016.10.016","volume":"109","author":"A del Pozo-Rodriguez","year":"2016","unstructured":"del Pozo-Rodriguez A, Solin\u00eds M\u00c1, Rodr\u00edguez-Gasc\u00f3n A. Applications of lipid nanoparticles in gene therapy. Eur J Pharm Biopharm. 2016;109:184\u201393.","journal-title":"Eur J Pharm Biopharm"},{"key":"3679_CR12","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"S Hoy","year":"2018","unstructured":"Hoy S. M. Patisiran: first global approval. Drugs. 2018;78:1625\u201331.","journal-title":"Drugs"},{"key":"3679_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"3679_CR14","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L, et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021;601:120586.","journal-title":"Int J Pharm"},{"key":"3679_CR15","doi-asserted-by":"publisher","first-page":"103553","DOI":"10.1016\/j.jddst.2022.103553","volume":"74","author":"B Wilson","year":"2022","unstructured":"Wilson B, Geetha KM. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. J Drug Deliv Sci Technol. 2022;74:103553.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3679_CR16","doi-asserted-by":"publisher","first-page":"100424","DOI":"10.1016\/j.dmpk.2021.100424","volume":"41","author":"Y Suzuki","year":"2021","unstructured":"Suzuki Y, Ishihara H. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs. Drug Metab Pharmacokinet. 2021;41:100424.","journal-title":"Drug Metab Pharmacokinet"},{"key":"3679_CR17","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1021\/bc700285q","volume":"18","author":"X-L Wang","year":"2007","unstructured":"Wang X-L, Ramusovic S, Nguyen T, Lu Z-R. Novel polymerizable surfactants with pH-sensitive amphiphilicity and cell membrane disruption for efficient siRNA delivery. Bioconjug Chem. 2007;18:2169\u201377.","journal-title":"Bioconjug Chem"},{"key":"3679_CR18","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1021\/mp400787s","volume":"11","author":"M Gujrati","year":"2014","unstructured":"Gujrati M, et al. Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release. Mol Pharm. 2014;11:2734\u201344.","journal-title":"Mol Pharm"},{"key":"3679_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jconrel.2013.06.019","volume":"171","author":"AS Malamas","year":"2013","unstructured":"Malamas AS, Gujrati M, Kummitha CM, Xu R, Lu Z-R. Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery. J Control Release. 2013;171:296\u2013307.","journal-title":"J Control Release"},{"key":"3679_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1021\/acs.bioconjchem.5b00538","volume":"27","author":"M Gujrati","year":"2016","unstructured":"Gujrati M, Vaidya A, Lu Z-R. Multifunctional pH-sensitive amino lipids for siRNA delivery. Bioconjug Chem. 2016;27:19\u201335.","journal-title":"Bioconjug Chem"},{"key":"3679_CR21","doi-asserted-by":"publisher","first-page":"2001294","DOI":"10.1002\/adhm.202001294","volume":"10","author":"ZR Lu","year":"2021","unstructured":"Lu ZR, Laney VE, Hall R, Ayat N. Environment-Responsive Lipid\/siRNA Nanoparticles for Cancer Therapy. Adv Healthcare Mater. 2021;10:2001294.","journal-title":"Adv Healthcare Mater"},{"key":"3679_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1021\/acs.bioconjchem.9b00028","volume":"30","author":"AM Vaidya","year":"2019","unstructured":"Vaidya AM, et al. Systemic delivery of tumor-targeting siRNA nanoparticles against an oncogenic LncRNA facilitates effective triple-negative breast cancer therapy. Bioconjug Chem. 2019;30:907\u201319.","journal-title":"Bioconjug Chem"},{"key":"3679_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.omtn.2017.02.005","volume":"7","author":"D Sun","year":"2017","unstructured":"Sun D, et al. Targeted multifunctional lipid ECO plasmid DNA nanoparticles as efficient non-viral gene therapy for Leber\u2019s congenital amaurosis. Mol Ther-Nucl Acids. 2017;7:42\u201352.","journal-title":"Mol Ther-Nucl Acids"},{"key":"3679_CR24","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/mabi.201500192","volume":"15","author":"D Sun","year":"2015","unstructured":"Sun D, et al. Self-Assembly of a Multifunctional Lipid With Core-Shell Dendrimer DNA Nanoparticles Enhanced Efficient Gene Delivery at Low Charge Ratios into RPE Cells. Macromol Biosci. 2015;15:1663\u201372.","journal-title":"Macromol Biosci"},{"key":"3679_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ymthe.2019.09.010","volume":"28","author":"D Sun","year":"2020","unstructured":"Sun D, et al. Non-viral gene therapy for Stargardt disease with ECO\/pRHO-ABCA4 self-assembled nanoparticles. Mol Ther. 2020;28:293\u2013303.","journal-title":"Mol Ther"},{"key":"3679_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1021\/acs.bioconjchem.8b00856","volume":"30","author":"D Sun","year":"2018","unstructured":"Sun D, et al. Synthesis and evaluation of pH-sensitive multifunctional lipids for efficient delivery of CRISPR\/Cas9 in gene editing. Bioconjug Chem. 2018;30:667\u201378.","journal-title":"Bioconjug Chem"},{"key":"3679_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/nat.2019.0784","volume":"29","author":"NR Ayat","year":"2019","unstructured":"Ayat NR, et al. Formulation of biocompatible targeted ECO\/siRNA nanoparticles with long-term stability for clinical translation of RNAi. Nucleic Acid Ther. 2019;29:195\u2013207.","journal-title":"Nucleic Acid Ther"},{"key":"3679_CR28","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s11095-021-03083-z","volume":"38","author":"AL Schilb","year":"2021","unstructured":"Schilb AL, et al. Efficacy of targeted ECO\/miR-200c nanoparticles for modulating tumor microenvironment and treating triple negative breast cancer as non-invasively monitored by MR molecular imaging. Pharm Res. 2021;38:1405\u201318.","journal-title":"Pharm Res"},{"key":"3679_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jconrel.2020.12.010","volume":"330","author":"D Sun","year":"2021","unstructured":"Sun D, et al. Formulation and efficacy of ECO\/pRHO-ABCA4-SV40 nanoparticles for nonviral gene therapy of Stargardt disease in a mouse model. J Control Release. 2021;330:329\u201340.","journal-title":"J Control Release"},{"key":"3679_CR30","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1021\/acsabm.0c00130","volume":"3","author":"D Sun","year":"2020","unstructured":"Sun D, et al. Stable retinoid analogue targeted dual pH-sensitive smart lipid ECO\/pDNA nanoparticles for specific gene delivery in the retinal pigment epithelium. ACS Appl Bio Mater. 2020;3:3078\u201386.","journal-title":"ACS Appl Bio Mater"},{"key":"3679_CR31","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/ph14101016","volume":"14","author":"AL Schilb","year":"2021","unstructured":"Schilb AL, et al. Optimization of Synthesis of the Amino Lipid ECO for Effective Delivery of Nucleic Acids. Pharmaceuticals. 2021;14:1016.","journal-title":"Pharmaceuticals"},{"key":"3679_CR32","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.omtn.2022.08.026","volume":"29","author":"D Sun","year":"2022","unstructured":"Sun D, et al. Effective gene therapy of Stargardt disease with PEG-ECO\/pGRK1-ABCA4-S\/MAR nanoparticles. Mol Ther-Nucleic Acids. 2022;29:823\u201335.","journal-title":"Mol Ther-Nucleic Acids"},{"key":"3679_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.oret.2019.02.007","volume":"3","author":"CY Weng","year":"2019","unstructured":"Weng CY. Bilateral subretinal voretigene neparvovec-rzyl (Luxturna) gene therapy. Ophthalmol Retina. 2019;3:450.","journal-title":"Ophthalmol Retina"},{"key":"3679_CR34","first-page":"1","volume":"30","author":"R Ladha","year":"2021","unstructured":"Ladha R, Meenink T, Smit J, de Smet MD. Advantages of robotic assistance over a manual approach in simulated subretinal injections and its relevance for gene therapy. Gene Ther. 2021;30:1\u20137.","journal-title":"Gene Ther"},{"key":"3679_CR35","doi-asserted-by":"publisher","first-page":"846782","DOI":"10.3389\/fmed.2022.846782","volume":"9","author":"R Ladha","year":"2022","unstructured":"Ladha R, Caspers LE, Willermain F, de Smet MD. Subretinal Therapy: Technological Solutions to Surgical and Immunological Challenges. Front Med. 2022;9:846782.","journal-title":"Front Med"},{"key":"3679_CR36","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.1167\/iovs.17-22402","volume":"58","author":"GA Ochakovski","year":"2017","unstructured":"Ochakovski GA, et al. Subretinal injection for gene therapy does not cause clinically significant outer nuclear layer thinning in normal primate foveae. Invest Ophthalmol Vis Sci. 2017;58:4155\u201360.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3679_CR37","doi-asserted-by":"publisher","unstructured":"M\u00fchlfriedel R, Michalakis S, Garrido MG, Biel M, Seeliger MW. Optimized technique for subretinal injections in mice. In: Weber B, Langmann T,\u00a0editors.\u00a0Retinal degeneration. Methods in molecular biology, vol 935. Totowa: Humana Press; 2012, pp.\u00a0343-349. https:\/\/doi.org\/10.1007\/978-1-62703-080-9_24","DOI":"10.1007\/978-1-62703-080-9_24"},{"key":"3679_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000479157","volume":"58","author":"Y Peng","year":"2017","unstructured":"Peng Y, Tang L, Zhou Y. Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases. Ophthalmic Res. 2017;58:217\u201326.","journal-title":"Ophthalmic Res"},{"key":"3679_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000431143","volume":"55","author":"CH Meyer","year":"2016","unstructured":"Meyer CH, Krohne TU, Issa PC, Liu Z, Holz FG. Routes for drug delivery to the eye and retina: intravitreal injections. Retinal Pharmacother. 2016;55:63\u201370.","journal-title":"Retinal Pharmacother"},{"key":"3679_CR40","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/bjophthalmol-2012-302030","volume":"96","author":"RG Abell","year":"2012","unstructured":"Abell RG, Kerr NM, Allen P, Vote BJ. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol. 2012;96:1474\u20138.","journal-title":"Br J Ophthalmol"},{"key":"3679_CR41","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.4103\/1673-5374.306063","volume":"16","author":"M Ross","year":"2021","unstructured":"Ross M, Ofri R. The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery. Neural Regen Res. 2021;16:1751\u20139. https:\/\/doi.org\/10.4103\/1673-5374.306063.","journal-title":"Neural Regen Res"},{"key":"3679_CR42","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.4103\/ijo.IJO_3117_20","volume":"69","author":"D Dhurandhar","year":"2021","unstructured":"Dhurandhar D, Sahoo NK, Mariappan I, Narayanan R. Gene therapy in retinal diseases: A review. Indian J Ophthalmol. 2021;69:2257\u201365. https:\/\/doi.org\/10.4103\/ijo.IJO_3117_20.","journal-title":"Indian J Ophthalmol"},{"key":"3679_CR43","doi-asserted-by":"crossref","unstructured":"Aziz AA. et al. Review of gene therapy clinical trials for retinal diseases. Int Ophthalmol Clin\u00a02024;64.","DOI":"10.1097\/IIO.0000000000000517"},{"key":"3679_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jconrel.2015.01.030","volume":"202","author":"TF Martens","year":"2015","unstructured":"Martens TF, et al. Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy. J Control Release. 2015;202:83\u201392.","journal-title":"J Control Release"},{"key":"3679_CR45","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/02713683.2020.1826977","volume":"46","author":"NK Tram","year":"2021","unstructured":"Tram NK, Maxwell CJ, Swindle-Reilly KE. Macro-and microscale properties of the vitreous humor to inform substitute design and intravitreal biotransport. Curr Eye Res. 2021;46:429\u201344.","journal-title":"Curr Eye Res"},{"key":"3679_CR46","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1073\/pnas.0308302101","volume":"101","author":"RA Radu","year":"2004","unstructured":"Radu RA, Mata NL, Bagla A, Travis GH. Light exposure stimulates formation of A2E oxiranes in a mouse model of Stargardt\u2019s macular degeneration. Proc Nat Acad Sci United States Am. 2004;101:5928\u201333. https:\/\/doi.org\/10.1073\/pnas.0308302101.","journal-title":"Proc Nat Acad Sci United States Am"},{"key":"3679_CR47","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/eye.1995.192","volume":"9","author":"CJ Kennedy","year":"1995","unstructured":"Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment epithelium: A review. Eye. 1995;9:763. https:\/\/doi.org\/10.1038\/eye.1995.192.","journal-title":"Eye"},{"key":"3679_CR48","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1073\/pnas.0737855100","volume":"100","author":"RA Radu","year":"2003","unstructured":"Radu RA, et al. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt\u2019s macular degeneration. Proc Nat Acad Sci. 2003;100:4742\u20137. https:\/\/doi.org\/10.1073\/pnas.0737855100.","journal-title":"Proc Nat Acad Sci"},{"key":"3679_CR49","first-page":"4579","volume":"43","author":"R Radu","year":"2002","unstructured":"Radu R, Mata N, Sieving P, Travis G. Treatment Of Abcr-\/- Mice With Isotretinoin Inhibits Accumulation Of Lipofuscin. Invest Ophthalmol Vis Sci. 2002;43:4579\u20134579.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3679_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.trsl.2012.12.007","volume":"161","author":"ME McClements","year":"2013","unstructured":"McClements ME, MacLaren RE. Gene therapy for retinal disease. Transl Res. 2013;161:241\u201354.","journal-title":"Transl Res"},{"key":"3679_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/OPTH.S38041","volume":"8","author":"H Petrs-Silva","year":"2013","unstructured":"Petrs-Silva H, Linden R. Advances in gene therapy technologies to treat retinitis pigmentosa. Clin Ophthalmol. 2013;8:127\u201336.","journal-title":"Clin Ophthalmol"},{"key":"3679_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00417-009-1158-7","volume":"248","author":"J Hillenkamp","year":"2010","unstructured":"Hillenkamp J, Surguch V, Framme C, Gabel V-P, Sachs HG. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2010;248:5\u201311.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3679_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-020-00745-9","volume":"19","author":"S Swetledge","year":"2021","unstructured":"Swetledge S, Jung JP, Carter R, Sabliov C. Distribution of polymeric nanoparticles in the eye: Implications in ocular disease therapy. J Nanobiotechnol. 2021;19:1\u201319.","journal-title":"J Nanobiotechnol"},{"key":"3679_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejps.2017.02.027","volume":"103","author":"TF Martens","year":"2017","unstructured":"Martens TF, et al. Effect of hyaluronic acid-binding to lipoplexes on intravitreal drug delivery for retinal gene therapy. Eur J Pharm Sci. 2017;103:27\u201335.","journal-title":"Eur J Pharm Sci"},{"key":"3679_CR55","doi-asserted-by":"publisher","first-page":"102181","DOI":"10.1016\/j.nano.2020.102181","volume":"26","author":"F Chaharband","year":"2020","unstructured":"Chaharband F, et al. Trimethyl chitosan-hyaluronic acid nano-polyplexes for intravitreal VEGFR-2 siRNA delivery: Formulation and in vivo efficacy evaluation. Nanomed Nanotechnol Biol Med. 2020;26:102181. https:\/\/doi.org\/10.1016\/j.nano.2020.102181.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"3679_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jconrel.2015.01.030","volume":"202","author":"TF Martens","year":"2015","unstructured":"Martens TF, et al. Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy. J Control Release. 2015;202:83\u201392. https:\/\/doi.org\/10.1016\/j.jconrel.2015.01.030.","journal-title":"J Control Release"},{"key":"3679_CR57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0008-4182(05)80119-X","volume":"40","author":"A \u00d6zkiri\u015f","year":"2005","unstructured":"\u00d6zkiri\u015f A, Erkili\u00e7 K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol. 2005;40:63\u20138.","journal-title":"Can J Ophthalmol"},{"key":"3679_CR58","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/ICU.0b013e328338679a","volume":"21","author":"KM Sampat","year":"2010","unstructured":"Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21:178\u201383.","journal-title":"Curr Opin Ophthalmol"},{"key":"3679_CR59","doi-asserted-by":"publisher","first-page":"26684","DOI":"10.1074\/jbc.M804505200","volume":"283","author":"A Maeda","year":"2008","unstructured":"Maeda A, Maeda T, Golczak M, Palczewski K. Retinopathy in Mice Induced by Disrupted All-trans-retinal Clearance. J Biol Chem. 2008;283:26684\u201393. https:\/\/doi.org\/10.1074\/jbc.M804505200.","journal-title":"J Biol Chem"},{"key":"3679_CR60","first-page":"131","volume":"7","author":"AM Timmers","year":"2001","unstructured":"Timmers AM, Zhang H, Squitieri A, Gonzalez-Pola C. Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina. Mol Vis. 2001;7:131\u20137.","journal-title":"Mol Vis"},{"key":"3679_CR61","first-page":"2211","volume":"14","author":"CJ Johnson","year":"2008","unstructured":"Johnson CJ, et al. Technical brief: subretinal injection and electroporation into adult mouse eyes. Mol Vis. 2008;14:2211\u201326.","journal-title":"Mol Vis"},{"key":"3679_CR62","first-page":"798","volume":"32","author":"J Moon","year":"2022","unstructured":"Moon J, Ramkumar S, von Lintig J. Genetic tuning of \u03b2-carotene oxygenase-1 activity rescues cone photoreceptor function in STRA6-deficient mice. Human Mol Gene. 2022;32:798\u2013809.","journal-title":"Human Mol Gene."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-024-03679-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T16:04:54Z","timestamp":1713369894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-024-03679-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3679"],"URL":"https:\/\/doi.org\/10.1007\/s11095-024-03679-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The gene therapy reported in this work was licensed to Helios BioPharmaceuticals for commercialization. ZRL may have ownership interest in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}